Amorphous 1,2-Dihydropyridine Compound Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The physical properties of 1,2-dihydropyridine compounds, such as crystal form or amorphous form, affect bioavailability and purity of drug substances, making it difficult to predict which form is useful for pharmaceutical development.
Innovation Solution
An amorphous form of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridine-2-one with excellent solubility in JP2 fluid is developed, characterized by the absence of diffraction peaks in X-ray powder diffraction, suitable for use as a therapeutic or prophylactic agent for neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If crystal form is used for the compound, then stability and purity are improved, but solubility and bioavailability deteriorate
Solution Approach 1:
The patent applies parameter changes by transforming the compound from crystalline form to amorphous form, fundamentally changing the physical state parameter. This transformation eliminates the ordered crystal lattice structure and creates a disordered molecular arrangement, which significantly improves solubility and bioavailability while maintaining stability through controlled amorphization processes
Solution Approach 2:
The invention utilizes phase transitions by converting the compound from solid crystalline phase to amorphous phase. This phase transition is achieved through specific processing methods such as rapid cooling, spray drying, or solvent evaporation, which trap the molecules in a disordered state, thereby enhancing solubility without sacrificing stability
2Object-affected harmful factors
If amorphous form is used for the compound, then solubility and bioavailability are improved, but manufacturing precision and characterization difficulty worsen
Solution Approach 1:
The patent applies preliminary action by pre-establishing controlled amorphization protocols and stabilization mechanisms before actual drug formulation. This includes pre-determining optimal processing parameters, selecting appropriate excipients that stabilize the amorphous state, and establishing quality control methods that can detect and ensure amorphous form presence, thereby making subsequent manufacturing more precise and controllable
3Adaptability or versatility
If various crystal forms are investigated, then pharmaceutical utility is improved, but development time and complexity increase
Solution Approach 1:
The patent applies the taking out principle by extracting the essential beneficial properties (solubility, bioavailability) from the amorphous form investigation and applying them directly to the 1,2-dihydropyridine compound without requiring exhaustive investigation of multiple crystal forms. This selective approach focuses resources on finding the optimal amorphous formulation rather than systematically exploring all possible crystalline polymorphs, thereby reducing development time while maintaining pharmaceutical utility
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The amorphous form of the compound demonstrates preferable properties, enhancing its suitability as an active ingredient for various neurodegenerative and other therapeutic applications, improving bioavailability and formulation design.
Implementation Method 1
having no diffraction peaks in an X-ray powder diffraction
Data Source
AI summary
An amorphous form of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridine-2-one.